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Edited by Lukas HuberAbstract We investigated topoisomerase IIa promoter activity
in epithelia. In conﬂuent human keratinocytes the promoter
(557 to+90 bp) was upregulated by oncogenicRas. In transgenic
mice expressingGFP via the promoter, GFP expression in undam-
aged epidermis was conﬁned to growing hair follicles. GFP was
also expressed in intestinal crypts. GFP expression was upregu-
lated in epidermis following wounding or phorbol ester treatment.
In each situationGFP expression correlated with high endogenous
topoisomerase IIa expression and high proliferation. The mice
therefore provide a useful model for non-invasive imaging of
regions of high proliferation in normal or damaged epidermis.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The topoisomerase II (topo II) enzyme plays an essential
role in DNA replication, chromatin condensation and segrega-
tion of sister chromatids [1]. Mammalian cells express two iso-
forms, topo IIa and topo IIb. Topo IIa is expressed at high
levels in tumours and is a major target of anticancer drugs [2].
Studies in culture have shown that topo IIa is expressed at
low levels in quiescent cells and is induced when cells are stim-
ulated to proliferate [3], being upregulated during S phase of
the cell cycle [4,5]. Topo IIa expression is markedly downreg-
ulated when cells become contact inhibited [6–8]. Conversely,
topo IIa levels are increased in NIH 3T3 cells transformed
by oncogenic Ras [9] and Ras increases topo IIa promoter
activity independently of the cell cycle [10].
The in vitro studies of topo IIa promoter activity suggest
that it might be a good reporter of proliferation or malignant
progression in mammalian epidermis. Maintenance of the epi-
dermis depends on stem cells, which proliferate at low levels in
undamaged skin but are responsible for epidermal repair fol-
lowing wounding and are also believed to drive tumour devel-
opment [11–13]. In mice, skin tumours can be induced by a two
stage chemical carcinogenesis protocol, in which Ras muta-
tions are induced with an agent such as 7,12-dimethyl-
benz[a]anthracence and tumours develop as a consequence
of repeated applications of a tumour promoter such as theAbbreviations: Topo IIa, topoisomerase IIa; eGFP, enhanced green
ﬂuorescent protein; TPA, 12-O-tetradecanoylphorbol-13-acetate
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[11,12,14]. Since the skin is readily accessible to examination,
we reasoned that the topo IIa promoter driving GFP expres-
sion might serve as a useful reporter of either normal or dam-
age-induced epidermal proliferation.2. Materials and methods
2.1. Cell lines
Wild type NIH 3T3 cells and NIH 3T3 cells transformed with H-Ras
bearing the valine 12 mutation (generous gift of Julian Downward) [15]
were maintained in DMEM and 10% donor calf serum. Human epider-
mal keratinocytes from newborn foreskin (strain u) transformed with
HPV alone (up cells) or in combination with H-Ras (upr) were cul-
tured in the absence of a feeder layer in FAD medium (1 part Hams
F12 plus 3 parts DMEM, supplemented with 1.8 · 104 M adenine)
supplemented with 10% FCS and HICE (0.5 lg/ml hydrocortisone,
5 lg/ml insulin, 1010 M cholera toxin and 10 ng/ml EGF), as de-
scribed previously [16,17].
2.2. Luciferase assays
Cells were seeded onto 6 well plates and the following day were tran-
siently transfected with 2 lg of PTIIa-557 topo IIa promoter in pGL2
luciferase vector (kind gift of Dennis Stacey) [5], or the pGL2 basic
control plasmid alone (Promega). Cells were co-transfected with
0.25 lg PJ7LacZ as a control for transfection eﬃciency. Cells were
transfected in Optimem (Gibco) with Superfect transfection reagent
(Qiagen), used according to the manufacturers instructions.
At 24, 48 or 72 h post transfection, cells were extracted in reporter
lysis buﬀer (Promega) that permitted luciferase and b-galactosidase
measurements to be performed on the same extracts. b-Galactosidase
and luciferase activity were determined using a BioOrbit 1251 lumino-
meter. 3T3 cells and keratinocytes were assayed 48 h post transfection,
except when the eﬀect of conﬂuence was to be determined, in which
case the assays were performed at 24 h (preconﬂuent) or 72 h (postcon-
ﬂuent).
2.3. Generation of topo IIa GFP mice
A K14 expression cassette was kindly provided by Elaine Fuchs. It
contained a 2100 bp AvaI fragment of the keratin 14 promoter/enhan-
cer, a rabbit b-globin 5 0 untranslated region (UTR), together with an
intronic sequence upstream of a BamHI site, and the K14 3 0 UTR, fol-
lowed by a polyadenylation site 3 0 downstream of the BamHI site [18].
The human topo IIa promoter was ampliﬁed from the pGL2 vector
(PTIIa-557 from Dennis Stacey) [5] by PCR using primers that con-
tained AvaI sites. The K14 promoter was excised using AvaI and re-
placed with the topo IIa promoter. Using PCR, BamHI restriction
sites were added to pEGFP-C1 (Clontech) and then enhanced green
ﬂuorescent protein (eGFP) was inserted into the BamHI site of the
transgene cassette.
Transgenic mice were generated by pronuclear injection of the puri-
ﬁed topo IIa-eGFP construct into fertilised oocytes from FVB/n mice.
Animals were screened for transgene expression by Southern blotting
performed on genomic DNA isolated from tail snips. Six founder linesblished by Elsevier B.V. All rights reserved.
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(4357A/5315, 4357A.3 and 4342b/5347) and 3 of which did not
(4342a, 4329.4 and 4329/5316). Lines 4357A/5315 and 4342b/5347 were
used for most experiments and gave similar results.
2.4. Immunohistochemistry
Immunohistochemistry was performed on paraﬃn sections of back
skin and small intestine using rabbit primary antibodies and horserad-
ish peroxidase conjugated secondary antibodies with DAB (Sigma) as
the chromogen. Sections were counterstained with haematoxylin. The
following antibodies were used: anti-GFP (Molecular Probes), anti-
lysozyme for staining Paneth cells (Dako), anti-Ki67 (Novacastra)
and anti-topo IIa (Novacastra). Prior to antibody staining, sections
were microwaved for 10 or (in the case of Ki67) 20 min in citrate buf-
fer. Goblet cells were visualised with Alcian blue (1% ﬁltered Alcian
blue in 3% acetic acid, pH 2.5) for 5 min.
2.5. Wounding and TPA treatment
Two 3 mm diameter full thickness wounds were made in the back of
each mouse. Mice were observed 2, 5, 7 and 14 days after wounding.
Two founder lines were studied, with two mice per founder line at each
time point after wounding. In some experiments histological sections
of 7-day-old wounds were prepared.
In some experiments, hair was removed from mouse back skin by
clipping and then 5 nmol TPA in 200 ll acetone was applied twice
weekly for 4 weeks.
2.6. Whole body imaging of wounds and small intestine
For whole body imaging, hair was removed from the skin by clip-
ping and Immac treatment in order to minimise the background ﬂuo-
rescence of the hair shafts. A small portion of upper small intestine was
excised from mice, rinsed in PBS and placed in a Petri dish. Images
were obtained with a Leica MZFIII stereomicroscope equiped with a
coolpix camera and Open Lab software.3. Results
3.1. Topo IIa promoter activity in cultured keratinocytes
It has previously been reported that a reporter construct
containing topo IIa promoter sequences from 557 to +90
gives maximal transcriptional activity in mouse ﬁbroblastic
cells [5] and is upregulated in the presence of oncogenic Ras
[10]. We were able to conﬁrm these observations by transiently
transfecting a topo IIa luciferase reporter into preconﬂuent
NIH 3T3 cells that were either wild type or expressed onco-
genic Ras (Fig. 1A). There was approximately 2-fold higher
luciferase activity in the presence of mutant Ras.up up
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Fig. 1. Activity of the topo IIa promoter in cultured cells and generation o
control of the topo IIa promoter in (A) NIH 3T3 cells that were wild type
transfected with HPV16 alone (up) or in combination with mutant Ras (upr
activity relative to control plasmid is shown. Data represent triplicate determin
transgene.In order to establish whether or not the promoter was also
active and Ras responsive in epithelial cells, we measured lucif-
erase activity in transiently transfected human epidermal
keratinocytes. We compared two lines of immortalised kerati-
nocytes that had been derived from the same individual. The
cells were transformed with HPV16 alone (up) or in combina-
tion with oncogenic Ras (upr) [16,17]. The promoter was more
active in keratinocytes (Fig. 1B and C) than in NIH 3T3 cells
(Fig. 1A). In preconﬂuent cultures there was 2–3-fold higher
luciferase activity in upr compared to up (Fig. 1B and C). Con-
sistent with previous studies in other cell types [8], promoter
activity in up cells decreased after conﬂuence (Fig. 1C). In con-
trast, topo IIa promoter activity was strongly upregulated in
postconﬂuent upr, resulting in a 7-fold increase relative to
postconﬂuent up (Fig. 1C).
The analysis of topo IIa promoter activity in cultured kerat-
inocytes suggested that it would be expressed in mammalian
epidermis and might be responsive to the proliferative or
Ras status of the cells. In order to examine this issue we gen-
erated the transgene construct shown in Fig. 1D, in which en-
hanced GFP was expressed under the control of the topo IIa
promoter.
3.2. Characterisation of topo IIa reporter mice
We generated a total of six founder lines, which fell into two
groups, according to whether transgene copy number was high
or low. In all three of the low copy number lines no GFP
expression was detected in undamaged or wounded skin (data
not shown) and therefore these lines were not pursued further.
Of the remaining three lines, two were compared in detail;
these gave similar results in all the assays performed (data
not shown).
In undamaged epidermis there was no detectable GFP
expression in the interfollicular epidermis and expression was
conﬁned to small numbers of cells at the base (bulb) of actively
growing follicles (Fig. 2A). This location was in good agree-
ment with the location of cells that had detectable levels of
endogenous topo IIa (Fig. 2B). In undamaged epidermis there
is a low level of proliferation in the basal layer of the interfol-
licular epidermis, and the region of highest proliferation, visu-
alised by expression of the Ki67 nuclear antigen, is in the bulb
of growing hair follicles (Fig. 2C). Thus GFP expression in
undamaged skin was conﬁned to the regions of the epidermisr
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f topo IIa transgene. (A–C) Activity of luciferase expressed under the
(wt) or expressed mutant (mt) Ras; (B,C) human keratinocytes stably
). (B,C pre): preconﬂuent; (C, post): postconﬂuent cultures. Luciferase
ations ± S.E.M. (D) Schematic representation of the topo IIa promoter
Fig. 2. Transgene expression in undamaged skin. Sections of back skin were stained with antibodies to the antigens shown. Boxed areas in left hand
panels are shown at higher magniﬁcation in right hand panels. Scale bar, 100 lm.
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highest (Fig. 2).
It was not possible to double label sections for Ki67 and
GFP because the antigen retrieval conditions required in order
to visualise Ki67 destroyed the GFP epitope. However, it was
clear that there was not extensive co-expression of Ki67 and
GFP, because only Ki67 positive cells were present in the inter-
follicular epidermis.
3.3. GFP expression in the small intestine
In order to investigate whether GFP expression was conﬁned
to the epidermis, we examined another epithelium that is re-
newed by stem cells, the lining of the small intestine [19]. In
those founder lines that had detectable GFP expression in
the epidermis, patches of GFP expression were clearly visible
when intact small intestines were examined under a dissecting
microscope with epiﬂuorescence illumination (Fig. 3A and B).
In cross sections of intestinal epithelium it was clear that
GFP expression was largely conﬁned to the crypts and absent
from the villi (Fig. 3C). The crypts are the region where prolif-
eration takes place [19] and corresponded to the region of highendogenous topo IIa expression (Fig. 3D). The location of
GFP expression in the crypts was conﬁrmed by labelling sec-
tions with antibodies to markers of two of the diﬀerentiated
cell types in the intestine. Paneth cells are located at the base
of the crypt (Fig. 3E), whereas goblet cells are present on the
villi (Fig. 3F). We conclude that the topo IIa promoter is ac-
tive in regions of high proliferative activity in both the epider-
mis and the small intestine.
3.4. Increased epidermal GFP expression in response to TPA
treatment
To examine whether the topo IIa promoter was activated in
hyperproliferative epidermis, we treated the back skin of trans-
genic mice with TPA. As previously reported [14], TPA treat-
ment resulted in thickening of the interfollicular epidermis and
increased proliferation (Fig. 4). This correlated with the
appearance of large numbers of GFP positive cells in the basal
and suprabasal layers of interfollicular epidermis and in the
hair follicles (Fig. 4A and B). Note that staining in the seba-
ceous glands was nonspeciﬁc, as it was detected in control
sections labelled with secondary antibody alone (Fig. 4A).
Fig. 3. Transgene expression in small intestine. (A,B) GFP expression in intact, freshly isolated small intestine. (C–F) Paraﬃn sections of small
intestine stained with antibodies to the antigens shown (brown). Section in F was counterstained with Alcian blue as a marker of goblet cells. Scale
bars 1 mm (A,B) and 100 lm (C–F).
Fig. 4. Eﬀect of TPA treatment on transgene expression. Dorsal skin was treated with 200 nmol TPA for 4 weeks prior to collection. (A) Secondary
antibody control, showing nonspeciﬁc staining of sebaceous glands. (B–D) staining with antibodies to the antigens shown. Areas surrounded by
dashed lines in B–D are shown at higher magniﬁcation in inserts. Scale bar: 100 lm.
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related well with an increased number of topo IIa positive cells
(Fig. 4C) and an increased number of Ki67 positive cells
(Fig. 4D).
As in undamaged skin (Fig. 2), there was not complete colo-
calisation with GFP and Ki67. Whereas the Ki67 positive cells
of the interfollicular epidermis were uniformly distributed and
largely conﬁned to the basal layer (Fig. 4D), the GFP positive
cells tended to be present in clusters, or patches, and included a
signiﬁcant number of suprabasal cells (Fig. 4B).
3.5. Induction of GFP expression during wound healing
We next examined whether GFP expression would be in-
duced by wounding the skin of transgenic mice, since this is
a situation in which epidermal proliferation is increased with
well-deﬁned kinetics [20]. Dual full thickness wounds were
made in the back skin of transgenic mice and 7 days later
the wounds were harvested for histological analysis (Fig. 5).
At this time point the wounds had not closed completely,
and the migrating front of epithelium on either side of theFig. 5. Transgene induction during wound healing. Sections of back skin we
antigens shown (A–C) or with H&E (D). Note that wound closure had not oc
at higher magniﬁcation in right hand panels. The clot covering the wound is
Scale bar: 100 lm (A–C), 400 lm (D).wound could readily be observed (Fig. 5). Large numbers of
GFP positive cells were present in the thickened, hyperproli-
ferative epidermis at the wound margins (Fig. 5A). As in
undamaged and TPA treated skin, the presence of GFP posi-
tive cells correlated with the presence of cells that were posi-
tively labelled with antibodies to endogenous topo IIa
(Fig. 5B) or the proliferation marker Ki67 (Fig. 5C). However,
as before, the GFP positive cells tended to be more clustered
than the Ki67 positive cells. During immunostaining the
wound clot was lost; however, it could be seen in H&E stained
sections of the wounds (Fig. 5D).
To determine whether topo IIa promoter activity could
potentially be used to monitor wound healing in live mice,
we imaged the back skin of transgenic animals killed at diﬀer-
ent times after wounding (Fig. 6). Mice were examined under a
dissecting microscope equipped with epiﬂuorescence illumina-
tion. In undamaged back skin the level of GFP ﬂuorescence
was too low to be detectable under the dissecting microscope
(data not shown), consistent with the histological analysis of
skin sections (Fig. 2). However, there was strong inductionre prepared 7 days after wounding and stained with antibodies to the
curred. Areas surrounded by dashed lines in left hand panels are shown
shown in (D), although it was lost during immunostaining in (A–C).
Fig. 6. Whole body ﬂuorescence imaging of wounds in the back skin of transgenic mice 5 (A,B), 7 (C,D) and 14 (E,F) days after wounding. Arrows
indicate position of wounds. Scale bars: 1 mm.
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all time points examined (Fig. 6). The area of GFP ﬂuores-
cence extended further than the immediate edges of the wound
and was particularly prominent in the hair follicles (see, for
example, Fig. 6C and E). There was some variability between
wounds, as illustrated by Fig. 6C and D, with some wounds
showing more extensive ﬂuorescence than others. However,
wound induced hyperproliferation could be readily monitored
by GFP expression in the transgenic mice.4. Discussion
We have shown that topo IIa promoter activity is a reporter
of regions of high proliferation and high endogenous topo IIa
expression in epidermis and small intestine. In undamaged
epidermis GFP expression was conﬁned to the base of growing
hair follicles, but expression was induced in the interfollicular
epidermis following the hyperproliferative stimuli of TPA
treatment or wounding. In the intestine expression was con-
ﬁned to the crypts, although the explanation for why only
some crypts were positive remains to be discovered.
While the transgene was an excellent reporter of regions of
high proliferation (the base of growing hair follicles, TPA trea-
ted interfollicular epidermis, and wound margins) it was not
expressed in every actively cycling epidermal cell. For example,
in normal skin there were Ki67 positive cells but no GFP po-
sitive cells in the interfollicular epidermis. This is an importantadvantage for live imaging of epidermal hyperproliferation,
because it means that background GFP ﬂuorescence is not a
problem.
The Ras responsiveness of the topo IIa promoter in cultured
keratinocytes raises the possibility that the mice could be used
as a noninvasive reporter to predict sites of development or
regression of benign or malignant skin tumours during chem-
ical carcinogenesis [14]. It is also possible that the mice would
have an application in visualising preneoplastic changes in the
intestine [19] or other epithelia. Finally, since topo IIa is a key
target of anticancer drugs [2], the mice may have applications
for drug screening.
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